Asiatic Laboratories Limited announcements
49 Dhaka Stock Exchange announcements for Asiatic Laboratories Limited (ASIATICLAB) since 2024: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (21).
- Regarding AGM Venue of the company
Refer to their earlier news disseminated by DSE on 02.11.2025 regarding dividend declaration, the company has further informed that the Annual General Meeting of the company will be held on the selected venue at EON Convention Center, 304, Bir Uttam Mir Shawkat Sarak, Tejgaon I/A, Dhaka-1208 (Besides of Channel I Head Office and Impulse Hospital) as well as virtually by using Digital Platform through the link: https://asiaticlab2025.hybridagmbd.net.
- Resumption after Record Date
Trading of the shares of the company will resume on 23.11.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 20.11.2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 18.11.2025 to 19.11.2025 and trading of the shares will remain suspended on record date i.e., 20.11.2025.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 1.24 for July-September 2025 as against Tk. 0.24 for July-September 2024; NOCFPS was Tk. 2.02 for July-September 2025 as against Tk. 0.60 for July-September 2024. NAV per share was Tk. 55.33 (with revaluation surplus) and Tk. 42.10 (without revaluation surplus) as on September 30, 2025, and Tk. 54.08 (with revaluation surplus) and Tk. 40.85 (without revaluation surplus) as on June 30, 2025. Significant deviation in EPS, NAVPS and NOCFPS: (cont.1) (cont. news of ASIATICLAB): NAVPS with Revaluation Surplus has been increased due to added of net profit after tax as at 30 September 2025, NAVPS without Revaluation Surplus has been increased due to added of net profit after tax as at 30 September 2025. NOCFPS has been increased due to increase of collection from customers for the period ended on 30 September 2025 compared to the preceding similar period ended on 30 September 2024 of the Company. (end) (cont. news of ASIATICLAB): EPS has been increased due to increase of the Net Profit after Tax, increase of deferred tax income, increase of sales revenue as well as acceleration of sales in new areas through establishment of new marketing areas as a policy of expanding the company business for the period ended on 30 September 2025 compared to the preceding similar period ended on 30 September 2024 of the Company. (cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 10, 2025 at 5:30 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Dividend Declaration
The Board of Directors has recommended 10% Cash dividend for all Shareholders excluding Directors and Sponsors for the year ended June 30, 2025. The Directors and Sponsors who shall not be entitled to the recommended Cash Dividend, hold 49,828,490 shares out of total 122,393,455 shares. The total amount of Cash Dividend to be payable to the General Shareholders and Independent Directors and only is Tk. 72,564,965.00 for 72,564,965 nos of ordinary shares. (cont.) (Cont. news of ASIATICLAB): Date of AGM: 24.12.2025, Time: 11:30 AM, Venue: Hybrid System (Venue will be informed later on). Record Date: 20.11.2025. The Company has also reported EPS of Tk. 2.09, NAV per share with revaluation surplus of Tk. 54.08, NAV per share without revaluation surplus of Tk. 40.85 and NOCFPS of Tk. 1.66 for the year ended June 30, 2025 as against Tk. 2.82, Tk. 52.58, Tk. 39.31 and Tk. 3.15 respectively for the year ended June 30, 2024. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (02.11.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 30, 2025 at 4:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2025
- Board approval for construction of 32 storied high-tech building
The company has informed that the Board of Directors in its meeting held on September 27, 2025 unanimously approved the construction of a new 32-storied high-tech building (name Time Square - Dhaka) will be constructed at 159/A. Tejgaon Commercial Area, Dhaka. The construction of the building will be on 20 katha land. (cont.) (Cont. News of ASIATICLAB): The board also approved a Joint Venture Agreement approved headed by the Managing Director of the on behalf of Asiatic Laboratories Limited (Owner of Land), with Headroom Limited (Bangladesh Consultant) and China State Construction Engineering Corporation (CSCEC) (For Building Construction) at the Head office of Asiatic Laboratories Limited on 27 September 2025. (end)
- Non-response to DSE's query on hike in price and volume of shares
This is for the information of all concerned that DSE sent a query letter regarding unusual hike in price and volume of shares to Asiatic Laboratories Limited on August 17, 2025. However, the company has not provided any response yet.
- Query Response
In response to the DSE query dated August 17, 2025, the company has informed via a letter received today i.e., August 19, 2025 that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.75 for January-March 2025 as against Tk. 0.59 for January-March 2024; EPS was Tk. 1.71 for July 2024-March 2025 as against Tk. 2.26 for July 2023-March 2024. NOCFPS was Tk. 1.73 for July 2024-March 2025 as against Tk. 2.06 for July 2023-March 2024. NAV per share with Revaluation was Tk. 53.71 as on March 31, 2025 and Tk. 52.58 as on June 30, 2024. NAV per share without Revaluation was Tk. 40.46 as on March 31, 2025 and Tk. 39.31 as on June 30, 2024. (cont.1) (Continuation news of ASIATICLAB): NOCFPS has decreased due to a decrease in collection from customers and an increase in the number of Ordinary Shares for the period ended on 31 March, 2025 compared to the preceding similar period ended on 31 March, 2024 of the Company. NAVPS with Revaluation Surplus has been increased due to added net profit after tax as of 31 March, 2025, NAVPS without Revaluation Surplus has been increased due to added net profit after tax as of 31 March, 2024. (end) (Continuation news of ASIATICLAB): Reasons for deviation in EPS, NOCFPS and NAVPS: EPS has been slightly changed due to a change of the Net Profit after Tax, deviation in deferred tax income/(expenses) as well as increase of operating expenses, Financial Expenses and an increase in the number of Ordinary Shares for the period ended on 31 March, 2025 compared to the preceding similar period ended on 31 March, 2024 of the Company. (cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2025 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.72 for October-December 2024 as against Tk. 0.62 for October-December 2023. EPS was Tk. 0.96 for July-December 2024 as against Tk. 1.54 for July-December 2023. NOCFPS was Tk. 0.87 for July-December 2024 as against Tk. 1.19 for July-December 2023. NAV per share (with revaluation surplus) was Tk. 52.95 as on December 31, 2024 and Tk. 52.58 as on June 30, 2024. NAV per share (without revaluation surplus) was Tk. 39.70 as on December 31, 2024 (cont.1) (Cont. news of ASIATICLAB): b) NOCFPS has decreased due to a decrease in collection from customers and an increase in the number of Ordinary Shares for the period ended on 31 December, 2024 compared to the preceding similar period ended on 31 December, 2023 of the Company. c) NAVPS with Revaluation Surplus has been increased due to added net profit after tax as of 31 December, 2024, NAVPS without Revaluation Surplus has been increased due to added net profit after tax as of 31 December, 2024. (end) (Cont. news of ASIATICLAB): and Tk. 39.31 as on June 30, 2024. Significant deviation in EPS, NOCFPS and NAVPS: a) EPS has been slightly changed due to a change of the Net Profit after Tax, deviation in deferred tax income/(expenses) as well as increase of operating expenses, Financial Expenses and an increase in the number of Ordinary Shares for the period ended on 31 December, 2024 compared to the preceding similar period ended on 31 December, 2023 of the Company. (cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on February 13, 2025 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
- Dividend Disbursement
The company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Category Change
The Company has been placed in 'A' category from existing 'Z' category with effect from today i.e., February 05, 2025 as the Company has reported disbursement of 10% Cash Dividend for the year ended June 30, 2024.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase the securities of Asiatic Laboratories Limited in between 1st to 7th trading days following the change of categorization, with effect from today i.e., February 05, 2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Category Change
The Company has been placed in 'Z' category from existing 'N' category with effect from today i.e., 29.01.2025 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024 regarding non-disbursement of the approved dividend within the stipulated time frame.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase securities of Asiatic Laboratories Limited with effect from today i.e., 29.01.2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.